X4 Pharmaceuticals Inc
NASDAQ:XFOR
Balance Sheet
Balance Sheet Decomposition
X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc
Balance Sheet
X4 Pharmaceuticals Inc
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
7
|
3
|
77
|
31
|
126
|
79
|
82
|
122
|
99
|
56
|
|
| Cash |
0
|
3
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
7
|
0
|
77
|
30
|
126
|
79
|
82
|
122
|
99
|
56
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
46
|
|
| Total Receivables |
2
|
1
|
2
|
3
|
2
|
1
|
1
|
1
|
1
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Other Current Assets |
0
|
1
|
1
|
2
|
1
|
4
|
5
|
6
|
7
|
6
|
|
| Total Current Assets |
8
|
6
|
80
|
35
|
129
|
83
|
88
|
129
|
122
|
112
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
2
|
9
|
10
|
8
|
6
|
5
|
|
| PP&E Gross |
1
|
1
|
0
|
0
|
2
|
9
|
10
|
8
|
6
|
5
|
|
| Accumulated Depreciation |
2
|
2
|
2
|
2
|
0
|
0
|
1
|
1
|
2
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
|
| Goodwill |
0
|
0
|
0
|
0
|
27
|
27
|
17
|
17
|
17
|
17
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
1
|
2
|
3
|
2
|
1
|
1
|
2
|
|
| Other Assets |
0
|
0
|
0
|
0
|
27
|
27
|
17
|
17
|
17
|
17
|
|
| Total Assets |
10
N/A
|
8
-20%
|
81
+970%
|
36
-56%
|
161
+346%
|
123
-24%
|
117
-5%
|
156
+33%
|
147
-5%
|
146
-1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
2
|
2
|
1
|
2
|
3
|
4
|
8
|
9
|
9
|
|
| Accrued Liabilities |
2
|
2
|
6
|
4
|
7
|
9
|
9
|
13
|
14
|
24
|
|
| Short-Term Debt |
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
2
|
2
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Other Current Liabilities |
2
|
3
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
7
|
12
|
11
|
5
|
9
|
12
|
14
|
22
|
23
|
33
|
|
| Long-Term Debt |
5
|
10
|
10
|
8
|
20
|
33
|
33
|
32
|
55
|
75
|
|
| Other Liabilities |
3
|
2
|
2
|
1
|
2
|
5
|
6
|
27
|
19
|
16
|
|
| Total Liabilities |
14
N/A
|
24
+75%
|
23
-7%
|
14
-36%
|
32
+119%
|
50
+59%
|
53
+5%
|
82
+54%
|
96
+18%
|
124
+29%
|
|
| Equity | |||||||||||
| Common Stock |
30
|
40
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
35
|
58
|
92
|
135
|
132
|
194
|
283
|
377
|
478
|
515
|
|
| Additional Paid In Capital |
0
|
1
|
151
|
157
|
261
|
267
|
347
|
451
|
529
|
537
|
|
| Other Equity |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
4
N/A
|
17
-280%
|
59
N/A
|
22
-63%
|
129
+498%
|
73
-44%
|
64
-12%
|
74
+15%
|
51
-31%
|
22
-57%
|
|
| Total Liabilities & Equity |
10
N/A
|
8
-20%
|
81
+970%
|
36
-56%
|
161
+346%
|
123
-24%
|
117
-5%
|
156
+33%
|
147
-5%
|
146
-1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
4
|
6
|
6
|
|